1-(1,4-Diazepan-1-yl)-2-methylpropan-1-one | 61903-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: 1-(1,4-Diazepan-1-yl)-2-methylpropan-1-one
• CAS: 61903-15-9
• 化学式: C₉H₁₈N₂O
• mdl: MFCD09045730
• 分子量: 170.25
• InChiKey: ZHQHWBADDPLOQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
  申请人：DYCK Brian

  公开号：US20110166116A1

  公开（公告）日：2011-07-07

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R 1 , R 2 , R 3 , n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明披露了一种新化合物，其在治疗患者的各种代谢相关疾病方面具有用途。本发明的化合物具有结构（I）：其中R1、R2、R3、n、p、q和Ar的定义如本文所述，包括立体异构体和药物可接受的盐。本发明还披露了包括本发明化合物的制药组合物，以及与在需要时使用该化合物的相关方法。
• ACRYLAMIDE COMPOUNDS AND THE USE THEREOF
  申请人：Mikamiyama Hidenori

  公开号：US20120022069A1

  公开（公告）日：2012-01-26

  The invention relates to acrylamide compounds of Formula I mentioned below. The invention is also directed to the use compounds of Formula I to treat or prevent a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及以下式子I的丙烯酰胺化合物。本发明还涉及使用式I的化合物来治疗或预防对钙通道阻滞有反应的疾病，尤其是N型钙通道。本发明的化合物特别适用于治疗疼痛。
• LRRK2 INHIBITORS
  申请人：Bounaud Pierre-Yves

  公开号：US20140205537A1

  公开（公告）日：2014-07-24

  Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases.

  本文提供了抑制或部分抑制富含亮氨酸重复激酶活性的化合物。本文还提供了治疗中枢神经系统疾病的方法，包括给予富含亮氨酸重复激酶抑制剂的治疗。
• THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160083375A1

  公开（公告）日：2016-03-24

  Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R 7 , are useful as kinase modulators, including IRAK-4 modulation.

  具有以下化学式的化合物：或其对映异构体、顺反异构体或药用可接受的盐，其中X为N或C—R7，可用作激酶调节剂，包括IRAK-4调节。
• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3354650A1

  公开（公告）日：2018-08-01

  The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

  本发明涉及可用作 ATR 蛋白激酶抑制剂的吡嗪化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物；使用本发明化合物治疗各种疾病、失调和病症的方法；制备本发明化合物的工艺；制备本发明化合物的中间体；以及在体外应用中使用本发明化合物的方法，例如研究生物和病理现象中的激酶；研究由这些激酶介导的细胞内信号转导途径；以及比较评估新的激酶抑制剂。 本发明的化合物具有式 I： 其中变量如本文所定义。